Abstract
This retrospective study aimed to evaluate potential hematological alterations in dogs treated with four different antineoplastic protocols. We selected 69 dogs that received at least four chemotherapy sessions and divided them into four groups: vinblastine (VBL) (n = 30), doxorubicin (DOX) (n = 15), combined CHOP protocol (cyclophosphamide, doxorubicin, vincristine, and prednisone) (n = 11), and vincristine group (VCR) (n = 13). Hematological parameters were recorded from blood samples collected in five periods: T0 (before the start of treatment), T1, T2, T3, and T4 (before each session). The VBL group showed a significant reduction in erythrocyte (p < 0.01), hematocrit (p < 0.01), and hemoglobin (p = 0.02) values, although mean values remained within the reference range. Data related to the DOX group did not show any significant changes during treatment. Dogs with lymphoma in the CHOP group presented values indicative of anemia at T0 (mean hematocrit of 36.8% and hemoglobin of 12.3 g/dL), with reduction throughout the treatment. While there was a significant reduction in the neutrophil count of the VCR group (p = 0.03), the mean values were not compatible with neutropenia. This study revealed adverse hematological effects related to the use of cytotoxic agents.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The data that support the findings of this study are openly available in Figshare, at https://doi.org/10.6084/m9.figshare.9761231.v3, which is referenced as follows:
[dataset] Kluthcovsky, L (2019): Complete blood count evaluation of dogs: four chemotherapy protocols. Figshare. Dataset. https://doi.org/10.6084/m9.figshare.9761231.v3
References
Adams VJ, Evans KM, Sampson J, Wood JLN (2010) Methods and mortality results of a health survey of purebred dogs in the UK. J Small Anim Pract 51:512–524. https://doi.org/10.1111/j.1748-5827.2010.00974.x
Baioni E, Scanziani E, Vicenti MC, Leschiera M, Bozzetta E, Pezzolato M, Desiato R, Bertolini S, Maurella C, Ru G (2017) Estimating canine cancer incidence: findings from a population-based tumour registry in northwestern Italy. BMC Vet Res 13(1):203. https://doi.org/10.1186/s12917-017-1126-0
Biller B, Berg J, Garret L, Ruslander D, Wearing R, Abbott B, Patel M, Smith D, Bryan C (2016) AAHA oncology guidelines for dogs and cats. J Am Anim Hosp Assoc 52(4):181–204. https://doi.org/10.5326/JAAHA-MS-6570
Blackwood L, Murphy S, Buracco P, DeVos JP, De Fornel-Thibaud P, Hirschberger J, Kessler M, Pastor J, Ponce F, Savary-Bataille K, Argyle DJ (2012) European consensus document on mast cell tumours in dogs and cats. Vet Comp Oncol 10(3):e1–e29. https://doi.org/10.1111/j.1476-5829.2012.00341.x
Cápua MLB, Coleta FED, Canesin APMN, Godoy AV, Calazans SG, Miotto MR, Daleck CR, Santana AE (2011) Canine lymphoma: clinical and hematological aspects and treatment with the Madison-Wisconsin protocol. Cienc Rural 14(7):1245–1251. https://doi.org/10.1590/S0103-84782011005000090
Cassali GD, Damasceno KA, Bertagnolli AC, Estrela-Lima A, Lavalle GE, DiSantis GW, De Nardi AB, Fernandes CG, Cogliati B, Sobral R, FVA C, Ferreira E, Salgado BS, Campos CB, D’Assis MJMH, Silva LP, Machado MCA, Firmo BF, Nunes FC, Nakagaki KYR (2017) Consensus regarding the diagnosis, prognosis and treatment of canine mammary tumors: benign mixed tumors, carcinomas in mixed tumors and carcinosarcomas. Braz J Vet Pathol 10(3):87–99. https://doi.org/10.24070/bjvp.1983-0246.v10i3p87-99
Chervier C, Cadoré JL, Rodriguez-Piñeiro B, Deputte BL, Chabanne L (2012) Causes of anemia other than acute blood loss and their clinical significance in dogs. J Small Anim Pract 53:223–227. https://doi.org/10.1111/j.1748-5827.2011.01191.x
Finora K (2003) Common paraneoplastic syndromes. Clin Tech Small Anim Pract 18(2):123–126. https://doi.org/10.1053/svms.2003.36629
Fournier Q, Serra JC, Handel I, Lawrence J (2018) Impact of pretreatment neutrophil count on chemotherapy administration and toxicity in dogs with lymphoma treated with CHOP chemotherapy. J Vet Intern Med 32(1):384–393. https://doi.org/10.1111/jvim.14895
Gustafson DL, Page RL (2013) Cancer chemotherapy. In: Withrow SJ, Vail DM, Page RL (eds) Small Animal Clinical Oncology, 5th edn. Elsevier, St. Louis, pp 157–161
Kimura KC, Gárate AP, Dagli MLZ (2012) Retrospective study of neoplasms in domestic animals: a survey between 1993 and 2002 of the service of animal pathology, Department of Pathology, School of Veterinary Medicine and Animal Science, University of Sao Paulo. Southeast Brazil Braz J Vet Pathol 5(2):60–69
Kiupel M, Webster JD, Bailey KL, Best S, DeLay J, Detrisac CJ, Fitzgerald SD, Gamble D, Ginn PE, Goldschmidt MH, Hendrick MJ, Howerth EW, Janovitz EB, Langohr I, Lenz SD, Lipscomb TP, Miller MA, Misdrop W, Moroff S, Mullaney TP, Neyens I, O’Toole D, Ramos-Vara J, Scase TJ, Schulman FY, Sledge D, Smedley RC, Smith K, Snyder PW, Southorn E, Stedman NL, Steficek BA, Stromberg PC, Valli VE, Weisbrode SE, Yager J, Heller J, Miller R (2011) Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behavior. Vet Pathol 48:147–155. https://doi.org/10.1177/0300985810386469
Kumar A (2016) Vincristine and vinblastine: a review. Int J Med Pharmaceut Sci 6(1):23–30
Miller AG, Morley PS, Rao S, Avery AC, Lana SE, Olver CS (2009) Anemia is associated with decreased survival time in dogs with lymphoma. J Vet Intern Med 23:116–122. https://doi.org/10.1111/j.1939-1676.2008.0210.x
O’neill DG, Guth A, Biller B, Elmslie R, Dow S (2013) Longevity and mortality of owned dogs in England. Vet J 198:638–643. https://doi.org/10.1016/j.tvjl.2013.09.020
Patnaik AK, Ehler WJ, MacEwen EG (1984) Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Vet Pathol 21:469–474. https://doi.org/10.1177/030098588402100503
Radakovich LB, Pannone SC, Truelove MP, Olver CS, Santangelo KS (2017) Hematology and biochemistry of aging: evidence of “anemia of the elderly” in old dogs. Vet Clin Pathol 46(1):34–45. https://doi.org/10.1111/vcp.12459
Šoštarić-Zuckermann IC, Severin K, Hohšteter M, Artuković B, Beck A, Kurilj AG, Sabocanec R, Dzaja P, Grabarević Z (2013) Incidence and types of canine tumours in Croatia. Vet Arhiv 83(1):31–45
Veterinary Cooperative Oncology Group (2016) Veterinary cooperative oncology group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Vet Comp Oncol 14(4):417–446. https://doi.org/10.1111/vco.283
Zachary JF, McGavin MD (2016) Pathologic basis of veterinary disease expert consult, 6th edn. Elsevier Health Sciences, St Louis, p 42
Funding
This study was funded in part by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior – Brasil (CAPES) – Finance Code 001.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This retrospective study was under the auspices of the Animal Use Ethics Committee of the Pontifical Catholic University of Parana, approved this project under protocol 01289/2018.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kluthcovsky, L.C., Machado, M.C.E., Silva, N.R.B. et al. Complete blood count evaluation of dogs treated with four different antineoplastic chemotherapy protocols. Comp Clin Pathol 29, 675–681 (2020). https://doi.org/10.1007/s00580-020-03107-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00580-020-03107-x